1. Home
  2. KRUS vs CABA Comparison

KRUS vs CABA Comparison

Compare KRUS & CABA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Kura Sushi USA Inc.

KRUS

Kura Sushi USA Inc.

HOLD

Current Price

$57.52

Market Cap

602.8M

ML Signal

HOLD

Logo Cabaletta Bio Inc.

CABA

Cabaletta Bio Inc.

HOLD

Current Price

$3.13

Market Cap

495.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KRUS
CABA
Founded
2008
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Restaurants
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
602.8M
495.7M
IPO Year
2019
2019

Fundamental Metrics

Financial Performance
Metric
KRUS
CABA
Price
$57.52
$3.13
Analyst Decision
Buy
Strong Buy
Analyst Count
9
6
Target Price
$81.11
$14.50
AVG Volume (30 Days)
453.4K
5.4M
Earning Date
04-07-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
79.75
10.26
EPS
N/A
N/A
Revenue
$282,763,000.00
N/A
Revenue This Year
$20.50
N/A
Revenue Next Year
$20.68
N/A
P/E Ratio
N/A
N/A
Revenue Growth
18.88
N/A
52 Week Low
$42.62
$1.26
52 Week High
$95.98
$4.23

Technical Indicators

Market Signals
Indicator
KRUS
CABA
Relative Strength Index (RSI) 60.27 48.87
Support Level $53.62 $3.12
Resistance Level $64.22 $3.34
Average True Range (ATR) 3.33 0.21
MACD 1.27 0.02
Stochastic Oscillator 79.65 69.61

Price Performance

Historical Comparison
KRUS
CABA

About KRUS Kura Sushi USA Inc.

Kura Sushi USA Inc is a technology-enabled Japanese restaurant concept that provides guests with a distinctive dining experience by serving authentic Japanese cuisine through an engaging revolving sushi service model. The company operates a chain of sushi restaurants across the United States serving freshly prepared Japanese cuisine using high-quality ingredients that are free from artificial seasonings, sweeteners, colorings, and preservatives. The company operates a network of dine-in locations across the U.S. states and Washington, DC.

About CABA Cabaletta Bio Inc.

Cabaletta Bio Inc is a late clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for autoimmune diseases. Its proprietary Cabaletta Approach to B cell Ablation (CABA) platform includes the CARTA approach, which uses chimeric antigen receptor T cells to eliminate B cells and potentially reset the immune system. The company develops cellular therapies including CAR T and CAAR T product candidates. Its candidate, rese-cel (resecabtagene autoleucel), a CD19-CAR T cell therapy, is being evaluated in Phase 1/2 trials for autoimmune diseases such as systemic lupus erythematosus, myositis, systemic sclerosis, generalized myasthenia gravis, and pemphigus vulgaris.

Share on Social Networks: